Seeking Alpha3d
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...
How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback
AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
BioPharma Dive2d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
BioSpace3d
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news
JPMorgan notes that AbbVie (ABBV) announced that its two Phase 2 EMPOWER trials evaluating emraclidine in schizophrenia did not meet their ...
BioPharma Dive3d
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...
AbbVie Says Phase 2 Trials Of Emraclidine In Schizophrenia Did Not Meet Primary Endpoint
Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a ...
biopharma-reporter2d
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
Buy, Sell, Or Hold AbbVie Stock?
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
STAT3d
Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.